Sanofi Files a Second Petition for IPR of Immunex’s Dupixent Patent

PTAB + IPR

Sanofi-Aventis has filed a petition for IPR of Immunex Corporation’s U.S. Patent 8,679,487, directed to isolated human antibodies that compete with a reference antibody for binding to human interleukin-4 (IL-4) receptor.  The proceeding has been assigned the number IPR2017-01879.  The ‘487 patent is also at issue in district court litigation regarding Sanofi-Aventis and Regeneron’s Dupixent (dipolumab), and in IPR2017-01129, also filed by Sanofi, as we’ve previously reported.

Dupixent® (dipolumab) is marketed by Sanofi-Aventis and Regeneron and is indicated for the treatment of atopic dermatitis.

The petition and other selected documents related to IPRs on biologic patents are posted on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.